PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|January 29, 2016
Final Rule on Covered Outpatient Drugs
January 29, 2016.
Advertisement
The advanced copy of the Final Rule on Covered Outpatient Drugs has been released by CMS.
Reserve your spot at CBI’s Final Rule Forum, February 22 in Philadelphia, to gain timely and critical insight into policy changes, operational implications, strategic impacts and best practices for compliance. CMS provides a Keynote Address, and leading manufacturers dive into the nuances of operationalizing the rule, providing a valuable opportunity to benchmark progress and key milestones in advance of the April 1 effective date.
Learn more at
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Advertisement
Advertisement
Trending on PharmExec
1
Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts
2
Bausch + Lomb Appoints Thomas Appio as Interim CEO
3
The Bottlenecks That Slow Manufacturer Response to Increased Demand for Production
4
The Manufacturing Issues That Continue to Contribute to Drug Shortages
5